Advertisement

Related Videos

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Peter Clark, MA, MD, FRCP: A Payer Perspective

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Advertisement

Advertisement




Jul
30
Today In Oncology
Germline Genetic Variants Associated With CAR T-Cell Therapy Safety and Efficacy in Hematologic Malignancies
FDA Approves SimpleScreen CRC Blood-Based Screening Test for Colorectal Cancer
MMUD vs MRD Transplantation in the Posttransplant Cyclophosphamide Era
Global Breast Cancer Survival Estimates: WHO Analysis
Concurrent Palliative Care Remains Underused Among Young Adults With Advanced Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo